Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | IDH1 | O75874 | 11/20 | 0.43 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2366268 | 1.00 | PIK3CA (0.44) | PIK3CAMTORIDH1PPARAHDAC1 | |
| SCHEMBL2366394 | 1.00 | PIK3CA (0.44) | PIK3CAMTORIDH1PPARAHDAC1 | |
| SCHEMBL14556276 | 0.83 | L3MBTL1 (0.50) | PIK3CAMTORIDH1PPARAHDAC1 | |
| SCHEMBL14556299 | 0.83 | L3MBTL1 (0.50) | PIK3CAMTORIDH1PPARAHDAC1 | |
| SCHEMBL14556277 | 0.83 | L3MBTL1 (0.50) | PIK3CAMTORIDH1PPARAHDAC1 | |
| SCHEMBL5854026 | 0.80 | PPARA (0.47) | PIK3CAMTORIDH1PPARAPPARG | |
| SCHEMBL5854036 | 0.80 | PPARA (0.47) | PIK3CAMTORIDH1PPARAPPARG | |
| SCHEMBL5604547 | 0.79 | IDH1 (0.55) | PIK3CAMTORIDH1 | |
| SCHEMBL5604553 | 0.79 | IDH1 (0.55) | PIK3CAMTORIDH1 | |
| SCHEMBL2366266 | 0.78 | PIK3CA (0.49) | PIK3CAMTORIDH1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2364975-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP2 | PIK3CA 4648/4885MTOR 3625/4885IDH1 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.